Introduction

With an incidence of 4% of all malignancies of the female genital tract, vulvar carcinoma is rather a rare form of cancer. From the histopathological point of view it is usually a squamous cell carcinoma, but adenocarcinomas, melanomas and carcinomas of the Bartholin glands may also occur in the vulvar region. Current projections for Germany assume about 3400–4000 new cases of vulvar cancer per year (A. Katalinic/U. Gerdemann: current statistics on vulvar cancer in Germany March 2011, cancer register [Aktuelle Zahlen zum Vulvakarzinom in Deutschland März 2011, Krebsregister]). These figures reflect the increasing occurrence of vulvar cancer over the past

with an incidence of 4% of all malignancies of the female genital tract, vulvar carcinoma is rather a rare form of cancer. From the histopathological point of view it is usually a squamous cell carcinoma, but adenocarcinomas, melanomas and carcinomas of the Bartholin glands may also occur in the vulvar region. Current projections for Germany assume about 3400–4000 new cases of vulvar cancer per year (A. Katalinic/U. Gerdemann: current statistics on vulvar cancer in Germany March 2011, cancer register [Aktuelle Zahlen zum Vulvakarzinom in Deutschland März 2011, Krebsregister]). These figures reflect the increasing occurrence of vulvar cancer over the past

Abstract

The rather rare vulvar cancer is almost always a squamous cell carcinoma that mostly develops from an underlying VIN or HPV infection. In addition, lichen sclerosus et atrophicans, immune deficiency, nicotine abuse or anogenital intraepithelial neoplasias may play a role in the pathogenesis. Surgical therapy aims at an R0 resection in the sense of a complete vulvectomy or a radical local excision with, if necessary, plastic reconstruction. Also, the vulvar field resection with consideration of the compartment model has been discussed. Besides the classic inguinofemoral lymphadenectomy, in selected cases of vulvar cancer sentinel biopsies are performed by experienced surgeons in the larger centres. In contrast, systemic therapy plays only a subordinate role; in isolated cases down-staging by means of neoadjuvant chemotherapy may be useful. However, there is at present no indication for adjuvant chemotherapy. Neoadjuvant radiochemotherapy is also not to be recommended on account of its unfavourable ratio of efficacy to side effects. On the other hand adjuvant radiotherapy is indicated in cases of positive inguinal lymph nodes. According to the current data the indication should be made generously in such cases.

Zusammenfassung

years [1–4]. In the past, especially women aged 70 years or more were afflicted, but in recent years the proportion of afflicted younger women has increased markedly. This is probably related to the fact that 40–60% of vulvar cancer and up to 90% of VIN cases are associated with HPV [1, 2, 5]. Among the vulvar cancers the following HPV subtypes in order of frequency have been identified: HPV subtypes 16, 33, 6, 18 and 31, with HPV 16 having the largest proportion of over 50% [6]. Other factors that may be involved in the development of vulvar cancer are, especially for older patients, lichen sclerosus et atrophicans, inherited or acquired immune deficiency, nicotine abuse or anogenital intra-epithelial neoplasias. Thus, in the past few years a bimodal age distribution has become increasingly apparent: a first peak at 45 to 50 years and a second peak at 70 to 75 years of age [7]. Staging is done in accordance with the FIGO and the TNM classifications. Decisive factors are the surgical findings and results of the histopathological analysis of surgical specimens.

**Operative Therapy**

**Stage-adapted therapy**

In principle, in the primary situation of surgical therapy for vulvar cancer, attempts should always be made to achieve an R0 resection. Only in exceptional cases such as, for example, an unacceptable risk of narcosis or in a palliative situation is primary radio(chemo)therapy indicated. For decades the standard surgical therapy consisted of an en-bloc resection of the vulva with bilateral inguinal lymphadenectomy (LNE). Because of the mutilating nature of this procedure and the numerous postoperative complications such wound-healing disorders (especially in obese female patients with diabetes), disturbances of bladder function, vaginal stenosis and chronic pain, a paradigm shift in favour of reduced surgical radicality has taken place during the past 10 to 15 years. Accordingly in most large centres the traditional en-bloc resection has been replaced by the so-called triple incision. Besides the vulvectomy dissection-shaped incision (Fig. 1), two separate incisions in the groin area are made for the inguinal LNE. This procedure, which has in the meantime advanced to be the standard, exhibits a markedly lower rate of wound-healing disorders. Since this procedure also leads to loss of the clitoris, in the sense of a further reduction in the radicality, at least in early tumour stages the triple incision is supplemented or, respectively, substituted by a radical local excision. In this procedure the tumour is resected macroscopically on all sides into healthy tissue. When this resection is widely performed it is also referred to as a partial vulvectomy. In a meta-analysis of data from 11 studies involving a total of 530 patients with T1 vulvar cancer, comparable rates of local recurrences were found for patients who underwent a radical local excision and those who, respectively, underwent a radical vulvectomy. The cancer-related mortality rates were also similar (0.6 vs. 0.5%) (7.2 vs. 6.3%) [8]. Depending on the localisation of the tumour, the radical local excision is classified as a partial anterior or a posterior vulvectomy or a hemivulvectomy. Although the radical local excision is now generally accepted it should be noted that only limited data are available on the progression-free or overall survival.

In clinical routine the following stage-adapted procedures are now established:

- **T1a**: radical local excision
- **T1b**: radical local excision, when in a median position with ipsi- or bilateral inguinal LNE
- **T2**: radical local excision with bilateral inguinal LNE and, if necessary, with pelvic LNE
- **T3/4**: radical vulvectomy with bilateral inguinal LNE and, if necessary, with pelvic LNE or also anterior/posterior or total exenteration

Independent of the surgical procedure, intraoperative macroscopic safety margins of 10 mm are recommended. In this way it is ensured that the 8-mm margins required by histology are still detectable even after artefacts from shrinking [9].

**Compartment model**

Similar to colon and cervix cancer, the compartment model is also under discussion for vulvar cancer. This model is based on the following theory. Malignancies spread over a relatively long period of time within the tissue compartments predetermined by embryonic development. In spite of their close spatial relationships, neighbouring compartments are at first not infiltrated by the tumour. The com-
plete removal of the respective morphogenetic unit or a segment of this compartment with minimal surgical trauma and retention of the neighbouring structures of different embryonic origin can result in an increased surgical radicality with reduced mortality. In cases of vulvar cancer three compartments can be distinguished: The deep compartment, that originates embryonically from the genital tubercle and from which the clitoris, bulbus and vestibulum develop, the superficial compartment originating from the urogenital folds which differentiate into the glans clitoridis, the labia minor and the inner sides of the labia major, and the lateral compartment, the origin of the outer sides of the labia major. Consideration of these embryonically predefined structures during the surgical or therapeutic planning in the sense of a vulvar field resection offers an enormous potential for increasing the surgical-oncological radicality and efficacy. It has been shown prospectively that, in about 50% of the patients in tumour stage T1–3, who underwent such a vulvar field resection with up to 50 months follow-up observation and 5% local morbidity, not one single local recurrence developed (with radical vulvectomy over all stages the rate is 25–35%) [10]. However, since the available data are limited and these results are all from a single centre, this procedure is not yet established as a standard and must still prove its value in the future. The surgical procedure in the framework of a posterior vulvar field resection with reconstruction is shown in Fig. 2.

Relevance of (Sentinel) Lymphadenectomy

In principle the lymph outflow of the vulva proceeds through the lymph nodes of the groin, which include both the superficial inguinal and the deeper femoral lymph nodes. The probability of lymphatic metastatic spread in this region does not depend on the tumour stage or, respectively, the visible tumour size. Solely for the infiltration depth has a positive correlation with positive groin lymph nodes been detected in numerous studies [11–13]. Thus, at an infiltration depth of > 1 mm (pT1b) the groin lymph nodes should be removed. This should be done in the sense of a bilateral systematic inguinalfemoral lymphadenectomy, since removal of merely the superficial inguinal lymph nodes carries a markedly higher risk of a prognostically very unfavourable groin recurrence. In such cases the removal of at least 6 lymph nodes of each type is recommended [14, 15]. Only for very small cancers with a far lateral localisation and free ipsilateral lymph nodes is it possible to omit the contralateral lymphadenectomy, since a very low rate (< 0.5%) of positive lymph nodes can be assumed [16–19].

Relevance of the pelvic lymphadenectomy

Lymph drainage of the vulva occurs almost exclusively via the inguinalfemoral lymph nodes. Only in cases of extensive disease is lymphatic metastatic spread via the femoral drainage pathways through to the external iliac veins and arteries in the direction of the pelvic lymph nodes to be expected. A communication via the plexus venosus vaginalis with the internal lymph nodes as is known in cases of vaginal carcinoma has not been described for vulvar cancer. Thus, with an incidence of 2% pelvic lymph node metastases are rather rare in early vulvar cancer of stage T1/T2 [20–22]. This results in a possible indication for pelvic lymphadenectomy only in cases with confirmed lymphogenic metastatic spread in the groin. Accordingly pelvic lymphadenectomy is recommended in cases with 3 or more positive unilateral groin lymph nodes, with capsule rupture, or with macrometastasis > 10 mm.

Sentinel lymphadenectomy

In principle, the concept of sentinel lymphadenectomy seems to be attractive also for vulvar cancer on account of the highly relevant postoperative morbidity of a systematic inguinalfemoral lymphadenectomy. Unfortunately, however, groin recurrences after sentinel lymphadenectomy alone have been reported in numerous publications [23–26]. Even so, the sentinel procedure is justified in tumour stages T1 and T2 according to the data of Zee et al. [27]. In the framework of this work involving over 400 patients the authors demonstrated a marked in morbidity with a 2.3% rate of groin recurrence. Since in the meantime also prospective data on this topic have become available [28], sentinel lymphadenectomy can be considered as an alternative to systematic bilateral inguinalfemoral lymphadenectomy in cases of vulvar cancer when the patients are informed adequately.

Systemic Therapy

On the whole, systemic therapy for primary vulvar cancer in the form of adjuvant or neoadjuvant chemotherapy has not had a history of success. Even so there have been isolated publications in the past few years concerning, above all, cisplatin, 5-FU or bleo-
mycin that may possibly redefine the role of systemic therapy for vulvar cancer. In the adjuvant situation it has been shown that a cisplatin monotherapy subsequent to surgical treatment may in individual cases with affected groin lymph nodes be a reasonable option also with regard to survival [29]. However, due to the small number of cases, the results of further studies must certainly be awaited. Neoadjuvant therapy is an interesting therapeutic concept, especially for advanced or, respectively, inoperable vulvar cancer [30–32]. The first objective here is a reduction of tumour size, which can then facilitate a subsequent local therapy or even change a primarily inoperable situation into a resectable finding, in such a case exenteration can be avoided and the patient’s quality of life improved. In addition, neoadjuvant chemotherapy can treat possibly present micrometastases and thus reduce the chances for distant metastatic spread [33–35]. However, due to the small number of patients, the use of neoadjuvant chemotherapy for vulvar cancer is still restricted to individual cases and further studies are needed.

**Radiation**

### Primary radiochemotherapy

In cases of local advanced vulvar cancer a primary radiochemotherapy, usually with cisplatin, 5-FU or also mitomycin C, may be employed. This may be indicated in patients with inoperable findings or to avoid a radical surgical intervention (exenteration) [36]. In spite of the high rate of clinical remissions of 46–91 % [37–41], residual tumours are frequently found on histopathology [40–42]. Thus, surgical sanitation should also follow directly after the primary radiochemotherapy; thus it is better in this context to refer to it as a neoadjuvant radiochemotherapy. All of the studies, although very heterogeneous with respect to study population and treatment schemes, have in common reported pronounced skin toxicity. Furthermore, randomised studies have shown no benefit in comparison with primary operations with regard to recurrence-free and overall survival [43], but they did reveal markedly higher rates of complications. Under consideration of the facts that the surgical procedure is more difficult after a prior radiation and that the option for radiation is still open in the case of a recurrence, a neoadjuvant radiochemotherapy remains reserved for exceptional cases.

### Adjuvant radiation

Together with micrometastases > 10 mm and a capsule rupture in the region of the inguinal lymph nodes and since the GOG study of Homesley et al. 1986, irradiation of the inguinal and pelvic lymph drainage pathways or a pelvic lymphadenectomy in combination with an inguinal radiotherapy are recommended in cases with 3 or more affected inguinal lymph nodes [44]. This procedure was the gold standard for a long time; however, since the ASCO 2012 and the results of the as yet largest multicentre study on nodal-positive vulvar cancer presented there, the indication for adjuvant radiation of the lymph drainage pathways has been expanded. In the AGO Care 1 Study a benefit of adjuvant radiation was observed independent of the number of positive lymph nodes. For this reason radiotherapy is now being discussed already for patients with just one affected inguinal lymph node. In addition, for R1 resection or marginal R0 resection without further surgical options, a subsequent radiation of the tumour bed should be carried out [45].

**Perspectives and Conclusion**

The management of vulvar cancer requires an interdisciplinary therapy in which surgery and radiotherapy play important roles. The precise significance of neoadjuvant chemotherapy needs to be clarified in further studies. Adjuvant radiation of the groin in the case of only one positive inguinal lymph node will certainly be a topic for future discussion.

**Acknowledgements**

We are grateful to Dr. Wolfgang Schmitt for provision of the graphic material.

**Conflict of Interest**

None.

**References**


32 Benedetti-Panici P, Greggi S, Scambia G et al. Cisplatin (P), bleomycin (B), and methotrexate (M) preoperative chemotherapy in locally advanced vulvar carcinoma. Gynecol Oncol 1993; 50: 49–53

33 Geisler JP, Manahan KJ, Buller RE. Neoadjuvant chemotherapy in vulvar cancer: avoiding primary exenteration. Gynecol Oncol 2006; 100: 53–57


